BiotechTube

SOC + TSC-100 + SOC + TSC-101

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

AML

Conditions

AML, Myelodysplastic Syndromes, ALL, Adult

Trial Timeline

Nov 1, 2022 → Jun 1, 2026

NCT ID
NCT05473910

About SOC + TSC-100 + SOC + TSC-101

SOC + TSC-100 + SOC + TSC-101 is a phase 1 stage product being developed by TScan Therapeutics for AML. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05473910. Target conditions include AML, Myelodysplastic Syndromes, ALL, Adult.

What happened to similar drugs?

2 of 14 similar drugs in AML were approved

Approved (2) Terminated (1) Active (11)
✅Venetoclax + AzacitidineAbbVieApproved
✅Olutasidenib + CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe SubstratesRigel PharmaceuticalsApproved
🔄Quizartinib + Salvage ChemotherapyDaiichi SankyoPhase 3
🔄gilteritinib + LoDAC (Low Dose Cytarabine) + Azacitidine + MEC (Mitoxantrone, Etoposide, Cytarabine) + FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)Astellas PharmaPhase 3
🔄gilteritinib + azacitidineAstellas PharmaPhase 3
🔄Gilteritinib + Cytarabine + Mitoxantrone + Etoposide + G-CSF + FludarabineAstellas PharmaPhase 3
🔄Venetoclax + Azacitidine + DecitabineAbbViePhase 3

Hype Score Breakdown

Clinical
6
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05473910Phase 1Recruiting

Competing Products

20 competing products in AML

See all competitors
ProductCompanyStageHype Score
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
14
AC220Daiichi SankyoPhase 1
29
Quizartinib + Salvage ChemotherapyDaiichi SankyoPhase 3
40
QuizartinibDaiichi SankyoPhase 1
29
gilteritinibAstellas PharmaPre-clinical
26
gilteritinibAstellas PharmaPre-clinical
26
Gilteritinib + Venetoclax + AzacitidineAstellas PharmaPhase 1/2
36
Gilteritinib + PlaceboAstellas PharmaPhase 2
35
Venetoclax + GilteritinibAstellas PharmaPhase 1
29
GilteritinibAstellas PharmaPhase 1
29
Gilteritinib + Ivosidenib + EnasidenibAstellas PharmaPhase 1
36
gilteritinib + LoDAC (Low Dose Cytarabine) + Azacitidine + MEC (Mitoxantrone, Etoposide, Cytarabine) + FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)Astellas PharmaPhase 3
40
gilteritinib + atezolizumabAstellas PharmaPhase 1/2
32
Gilteritinib + Venetoclax + Azacitidine (AZA) + Local standard of care (SOC)Astellas PharmaPhase 2/3
45
gilteritinib + fludarabine + cytarabine + granulocyte colony-stimulating factor (G-CSF)Astellas PharmaPhase 1/2
24
ASP2215Astellas PharmaPre-clinical
26
ASP7517Astellas PharmaPhase 1/2
32
gilteritinib + azacitidineAstellas PharmaPhase 3
40
Gilteritinib + Cytarabine + Mitoxantrone + Etoposide + G-CSF + FludarabineAstellas PharmaPhase 3
44
decitabine Induction Chemotherapy + Induction ChemotherapyEisaiPhase 2
27